Fecal calprotectin (fCal) is an essential biomarker for monitoring inflammatory bowel disease (IBD), helping ensure patients receive the right treatment at the right time.
As patient-centered care grows, remote monitoring tools like the CalproSmart self-test offer an efficient alternative to traditional lab-based methods. But do these two different analyses give the same fCal results?
This study compares the CalproSmart self-test with the CalproLab ELISA assay, both developed by Calpro, to assess their agreement in measuring fCal levels. The findings demonstrate that both methods produce reliable and consistent results, ensuring they can be used interchangeably without affecting clinical outcomes.
